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The urokinase plasminogen activator system plays a central role in malignant tumour progression. Both tumour hypoxia and
enhancement of urokinase plasminogen activator, urokinase plasminogen activator-receptor and plasminogen activator inhibitor
type 1 have been identiﬁed as adverse prognostic factors. Upregulation of urokinase plasminogen activator or plasminogen
activator inhibitor type 1 could present means by which hypoxia inﬂuences malignant progression. Therefore, the impact of
hypoxia on the expression pattern of the urokinase plasminogen activator system in rat DS-sarcoma in vivo and in vitro was
examined. In the in vivo setting, tumour cells were implanted subcutaneously into rats, which were housed under either
hypoxia, atmospheric air or hyperoxia. For in vitro studies, DS-sarcoma cells were incubated for 24 h under hypoxia. Urokinase
plasminogen activator and urokinase plasminogen activator-receptor expression were analysed by ﬂow cytometry. Urokinase
plasminogen activator activity was measured using zymography. Plasminogen activator inhibitor type 1 protein levels in vitro
and in vivo were examined with ELISA. PAI-1 mRNA levels were determined by RT–PCR. DS-sarcoma cells express
urokinase plasminogen activator, urokinase plasminogen activator-receptor, and plasminogen activator inhibitor type 1 in vitro
and in vivo. The urokinase plasminogen activator activity is enhanced in DS-sarcomas compared to normal tissues and rises
with increasing tumour volume. The oxygenation level has no impact on the urokinase plasminogen activator activity in
cultured DS-sarcoma cells or in solid tumours, although in vitro an increase in plasminogen activator inhibitor type 1 protein
and mRNA expression after hypoxic challenge is detectable. The latter plasminogen activator inhibitor type 1 changes were
not detectable in vivo. Hypoxia has been demonstrated to contribute to the upregulation of some components of the system
in vitro, although this effect was not reproducible in vivo. This may indicate that the serum level of plasminogen activator
inhibitor type 1 is not a reliable surrogate marker of tumour hypoxia.
British Journal of Cancer (2002) 86, 1355–1361. DOI: 10.1038/sj/bjc/6600237 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: urokinase plasminogen activator; plasminogen activator inhibitor type-1; urokinase plasminogen activator receptor;
hypoxia; DS-sarcoma; malignant progression
Tumour invasion, malignant progression and distant metastasis
depend on complex multistep processes. One prerequisite is the
ability of tumour cells to initiate extracellular proteolysis which
is required for the crossing of tissue barriers, migration, invasion,
tissue remodelling and angiogenesis. There is abundant experimen-
tal evidence that serine proteases of the urokinase-plasminogen
activator system play a major role in malignant progression and
tumour metastasis (Andreasen and Petersen, 2000).
The urokinase-plasminogen activator (uPA) is secreted in a
zymogen form as inactive single-chain proenzyme (pro-uPA) by
tumour and/or by stromal cells and is converted by limited
proteolytic cleavage into the active two-chain enzyme. It binds
to the urokinase plasminogen activator receptor (uPAR), which
is located on the surface of tumour cells, and also on cells of
the tumour stroma. The binding to the receptor leads to a
massive enhancement of proteolytic activity, providing an efﬁcient
and locally focussed proteolysis. The main target of uPA is plas-
minogen, which is converted into plasmin. Urokinase-
plasminogen activator is also involved in the activation of hepato-
cyte growth factor/scatter factor (HGF/SF). Plasmin is able to
cleave a variety of proteins of the extracellular matrix (ECM) such
as collagen type IV, laminin, ﬁbronectin and vitronectin and is
also involved in the conversion of some matrix-metalloproteinases
from the zymogen pro-form into active enzymes and in the acti-
vation of latent TGFb or in the release of bFGF from ECM-
binding sites.
The proteolytic activity of the uPA/uPAR complex is regulated
by so-called serpins (plasminogen activator inhibitor type I (PAI-
1) and type II (PAI-2)). The binding of PAI induces the internali-
sation of the uPA/uPAR complex, intracellular degradation of uPA
and the recycling of the uPAR to the cell membrane (for a review
see Andreasen et al, 1997).
An upregulation of uPA and/or uPAR has been described for
many human tumours. High levels of uPA and uPAR in tumour
tissue (and also in plasma) are associated with poor prognosis of
patients with cancers of the breast, head and neck, uterine cervix,
bladder, lung, ovary or with soft tissue sarcoma (for a review see
Reuning et al, 1998). Paradoxically, many studies also identiﬁed
enhanced levels of PAI-1, but not PAI-2, as an adverse prognostic
factor (Reuning et al, 1998). The role of PAI-1 in tumour progres-
sion is not yet fully understood. Additional functions beyond the
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www.bjcancer.cominvolvement in proteolysis may explain the tumour-promoting role
of PAI-1 (Bajou et al, 1998).
So far, the events leading to an enhanced expression of uPA,
uPAR or PAI-1 in solid tumours have not been fully elucidated.
Cytokines and oncogenes are able to induce components of the
uPA-system (Reuning et al, 1998), but the trigger mechanisms
for upregulation could also be derived from the speciﬁc tumour
micro-environment.
Most tumours are characterised by low extracellular pH, glucose
depletion, high lactate levels and regions with low oxygen tensions
(Vaupel et al, 1989, 1992, 1998). Low oxygen tensions in human
tumours have been associated with poor outcome (e.g. Ho ¨ckel et
al, 1993, 1996; Nordsmark and Overgaard, 2000; Nordsmark et
al, 2001), enhanced local or locoregional spread (Ho ¨ckel et al,
1999) and enhanced metastatic potential (Brizel et al, 1996; Sund-
for and Rofstad, 1998; Rofstad, 2000).
Tumour hypoxia is a key parameter, able to modulate the
expression of a variety of genes which are involved in tumour
angiogenesis, malignant progression and distant metastasis (Dachs
and Tozer, 2000; Koong et al, 2000; Ho ¨ckel and Vaupel, 2001).
Some components of the uPA-system have also been shown to
be induced by hypoxia in a number of cell lines in vitro (Graham
et al, 1998, 1999; Kietzmann et al, 1999; Maity and Solomon,
2000).
The aim of this study is the characterisation of the expression of
uPA, uPAR and PAI-1 in rat DS-sarcoma in vitro and in vivo (i.e.,
from tumour cell culture to the solid tumour), the identiﬁcation of
the main cellular source in solid DS-tumours and the examination
of the dependency of uPA, uPAR and PAI-1 expression on micro-
environmental factors such as oxygenation status.
MATERIALS AND METHODS
Animals and tumours
0.4 ml of haemorrhagic ascites of syngenic DS-sarcoma cells
(10
4 cells ml
71) were injected s.c. into the hind foot dorsum of
Sprague Dawley rats (6–8 weeks of age, body weight 180–200 g,
Charles River, Sulzfeld, Germany). Tumours were measured daily
using precision callipers, and were excised once a volume of
between 1 and 2 ml was reached (for experiments evaluating the
impact of volume, tumours between 0.5 and 3.5 ml were used).
Immediately after excision single cell suspensions were prepared
for ﬂow cytometry, or alternately tumours were frozen in liquid
nitrogen and stored at –808C. For experiments examining the role
of the oxygenation status, animals were housed during the whole
period of tumour growth in a hypoxic atmosphere (8% O2/92%
N2), normal room air or under hyperoxic conditions (100% O2)
for 7–12 days. All animal experiments performed had been
approved by the regional ethics committee according to German
federal law. The ethical guidelines that were followed meet the
standards required by the ‘United Kingdom Committee on Cancer
Research (UKCCCR) guidelines for the welfare of animals in
experimental neoplasia’ (Workman et al, 1998).
Hypoxic cell culture
To establish hypoxic conditions in vitro, a gas-proof stainless steel
chamber inside an incubator was ﬂushed with a prewarmed and
water saturated gas mixture of &95% N2/&5% CO2 and 50.1%
O2. After an initial peak, the gas ﬂow was adjusted to 0.5 l h
71
and the time course of oxygen washout was measured. DS-sarcoma
cells were isolated from solid tumours and grown in vitro. For
hypoxic challenge of DS-sarcoma cells, three petri dishes
(2610
5 cells ml
71 medium, Petri Perm
TM, Heraeus, Hanau,
Germany) were placed into the hypoxic chamber for 24 h. The
hypoxic period commenced (t0=0 h) when the gas ﬂow was
started. Under these conditions, after a wash out period of 2 h,
the O2 concentration in the chamber was below 1%. Control cells
were incubated under a normal atmospheric oxygen concentration
(H2O saturated room air, 5% CO2).
Indirect ﬂow cytometry of uPA and uPAR
Single cell suspensions of solid tumours were prepared and
contaminating red blood cells removed using an RBC lysis buffer.
The suspension was adjusted to give a concentration of 0.5–
1610
6 cells ml
71 in phosphate buffered saline supplemented with
1% glucose, washed twice and stained with either uPA (sc-6831
Santa Cruz Biotech., Santa Cruz, CA, USA), uPAR polyclonal
IgG antibody (sc-9795 Santa Cruz Biotech., Santa Cruz, CA,
USA) or normal goat IgG antibody (sc-2028 Santa Cruz Biotech.,
Santa Cruz, CA, USA) as negative controls. Both antibodies were
detected with a FITC-labelled donkey anti-goat IgG antibody (sc-
2024 Santa Cruz Biotech., Santa Cruz, CA, USA) and measured
using ﬂow cytometry (Coulter EPICS Proﬁle, Beckman Coulter,
Palo Alto, CA, USA).
One-phase uPA zymography
Whole cell protein extracts were prepared from 20 mm cryosections
of solid tumours or from washed cell suspensions by incubating the
homogenised cell material for 45 min at 48C in a lysis buffer
(0.01 M HEPES, 0.25 M Sucrose, 0.5% v v
71, Triton X-100,
pH 7.2). Debris was removed by centrifugation (150006g) for
15 min at 48C and supernatants were stored at 7808C. Protein
content was determined by a DC protein assay (BioRad, Hercules,
CA, USA) and adjusted to 1 mg ml
71 for zymography. Seven mlo f
cell lysates or cell culture supernatants were run on a 10% SDS–
PAGE containing 0.3% casein and 0.025 U ml
71 Lys-plasminogen
under non-reducing conditions together with prestained molecular
weight markers (BioRad, Hercules, CA, USA). Gels were washed
after electrophoresis in a washing buffer (Triton X-100 2.5%,
0.1 M TRIS–HCl, pH 8.1) for 2615 min and incubated overnight
in 10 mM CaCl2,5 0m M TRIS–HCl (pH 8.1) at room tempera-
ture. The gels were stained with 0.1% Coomassie Blue, so that
zones of uPA activity occurred as clear lysis zones on a blue back-
ground. The bands were quantiﬁed densitometrically (Bio IQ
Quantiﬁer, B.I. Systems Corporation, Ann Arbor, MI, USA). For
controls, parallel samples were loaded on gels without plasmino-
gen. To speciﬁcally determine uPA levels also control gels which
contained 2 mM amiloride were also used. Amiloride selectively
inhibits uPA but does not affect other plasminogen activators
(Vassalli, 1987).
PAI-1–ELISA
Whole cell protein lysates were prepared as described above. PAI-1
protein concentration in cell culture supernatant, Triton extracts
(0.01 M HEPES, 0.25 M Sucrose 0.5% v v
71, Triton X-100,
pH 7.2) of solid DS-sarcomas or DS-sarcoma cells in culture, or
in rat serum have been determined by a rat-speciﬁc PAI-1 sand-
wich ELISA (American Diagnostica, Pfungstadt, Germany)
according to the manufacturer’s recommendations.
RT–PCR analysis
RNA extraction RNA was isolated from washed cell suspensions
or cryosections of solid DS-sarcomas by the guanidinium isothio-
cyanate method using the Qiagen RNeasy extraction kit (Qiagen,
Hilden, Germany) according to the manufacturer’s recommenda-
tions. RNA content and purity was determined by photometry at
260 vs 280 nm.
Reverse transcription 1 mg of total RNA was incubated with
50 pmoles of random hexamers for 15 min at 658C. The mixture
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added containing PCR-buffer, 1 U Rnase inhibitor, 15 U MuLV
reverse transcriptase, 10 mM MgCl2,1 m M PCR nucleotide mix
and double-distilled water up to a volume of 30 ml (all biochem-
icals from Applied Biosystems, Welterstadt, Germany, except
dNTP which was supplied by Roche, Mannheim, Germany).
Reverse transcription was carried out in a thermal cycler (Biome-
tra, Go ¨ttingen, Germany) for 1 h at 408C with an additional
5 min-step at 998C for inactivation of the reverse transcriptase.
cDNA was subsequently stored at 7208C.
PCR primers For pseudogene-free ampliﬁcation of rat
b-actin cDNA, previously published primers have been used (Raff
et al, 1997) (b-actinsense: tacaacctccttgcagctcc, b-Actinantisense:
ggatcttcatgaggtagtctgtc). PAI-1 primers were constructed from
published sequences of the rat genome (Genbank accession no.
M24067 (Brudzinski et al, 1990) PAI-1sense: tttgggaaagggttcgcttc
PAI-1antisense: agtcgttgatgatgaatctgg, intron spanning). Sequence
identity of the constructed primers was checked by excising bands
from the gel, followed by DNA sequencing. Negative controls with
RT (7)-template were carried out to check possible co-ampliﬁ-
cation of genomic DNA.
PCR Following an initial denaturation period of 3 min at 958C,
PCR was carried out in a thermal cycler (Biometra, Go ¨ttingen,
Germany) at 958C/30 s, 608C 1 min and 728C/30 s. A ﬁnal exten-
sion period of 728C/7 min was performed at the end of each PCR
reaction. One PCR sample of 25 ml volume contained a mixture of
2.4 mM MgCl2 and PCR buffer (Applied Biosystems, Welterstadt,
Germany), 0.8 mM dNTP-mix (Roche, Mannheim, Germany) and
0.1 mg cDNA. PCR primers were added up to an amount of
10 pmol each.
Fragment detection and evaluation One per cent agarose gels
stained with ethidium bromide were run for 90 min at 60 V.
PCR products were visualized on a UV-screen by means of a
digital camera and attached hardware (Intas, Go ¨ttingen,
Germany). Densitometrical evaluation was performed using image
processing software (Bio IQ Quantiﬁer, B.I. Systems Corporation,
Ann Arbor, MI, USA). To ensure the speciﬁcity of the ampliﬁca-
tion b-actin and PAI-1 band were excised from the gel and
sequenced.
Semi-quantitative multiplex RT–PCR For a semi-quantitative
analysis of PAI-1 mRNA in solid tumour or isolated DS-sarcoma
cells in vitro, a non-competitive RT-PCR method in the presence
of two pairs of primers for PAI-1 mRNA and for b-Actin mRNA
as internal standard was performed. Each PCR-mix was split into
six fractions, undergoing PCR for 18, 21, 24, 27, 30 or 33 PCR
cycles respectively, followed by agarose gel electrophoresis and
densitometry. After plotting the data-points (band intensity) vs
PCR-cycles, curve ﬁts were performed on the computer in order
to generate a PCR-ampliﬁcation curve for every target. For each
ampliﬁcation graph, a threshold cycle number was extrapolated,
corresponding to a threshold value just above the densitometrical
background. For every specimen, the calculated difference between
the respective threshold cycle of b-actin and PAI-1 was regarded as
a measure of PAI-1 gene expression: DPAI-1=PAI-1[threshold
cycle no.]–b-actin [threshold cycle no.].
Statistical analysis
Urokinase plasminogen activator and uPAR expression on the cell
surface compared to negative controls were analysed with a paired
sample t-test. Zymographic uPA activity in the different groups
was analysed by a Wilcoxon test for paired samples, and PAI-1
protein concentration in the different groups of samples was
compared by the Mann–Whitney test using SPSS 10.0 statistical
software.
RESULTS
Expression of uPA, uPAR and PAI-1 by DS-sarcoma cells
Expression of uPA, PAI-1 and uPAR was examined in solid DS-
sarcoma and in DS-sarcoma cells in vitro. Surface expression of
uPAR and uPA was detected in both DS-sarcoma cells derived
from cell culture (Figure 1) and, to a comparable extent, on cells
isolated from solid DS-sarcomas (data not shown). Histological
examination of DS-sarcomas demonstrated that the proportion of
tumour stroma is quite low in these tumours and the comparison
of the uPA and uPAR surface expression by ﬂow cytometry exhi-
bits no signiﬁcant difference in the mean ﬂuorescence activity
between DS-tumour cells isolated from solid tumours and DS-
sarcoma cells grown in culture. This indicates that most of uPA
and uPAR in the samples derives from tumour cells, rather from
leukocytes or stromal cells.
The zymography of crude whole cell protein extracts (7 mg/total
protein per sample) from solid DS-sarcomas exhibited two plasmi-
nogen-dependent proteolytic bands, one with strong, another with
weak proteolytic activity in the 50 kDa region. Adding 2 mM/ml
amiloride to the SDS–PAGE abrogates the proteolytic activity of
the strong lysis zone completely, while the weak band was not
inﬂuenced at all, indicating that this strong lysis zone represents
the proteolytic activity of uPA (Figure 2). Similar bands were
found in protein extracts of DS-sarcoma cells in vitro (data not
shown).
DS-sarcoma cells also express PAI-1. Plasminogen activator inhi-
bitor type 1 protein could be detected in total protein extracts of
solid DS-tumours, but also in whole cell lysate of cultured DS-
sarcoma cells (by ELISA). The highest amount of PAI-1 protein
was found in cell culture supernatants of DS-sarcoma cells in vitro.
Not only PAI-1 protein but also PAI-1 mRNA was found in
both RNA extracts from solid DS-tumours and RNA extracts of
DS-sarcoma cells in vitro by RT–PCR, indicating that PAI-1 is also
produced by the tumour cell itself. Since RT–PCR reactions with
PAI-1 primers showed no co-ampliﬁcation of genomic DNA, the
possibility of false positive results can thus be disregarded.
uPA activity in DS-sarcoma cells in vitro and in solid
tumours
Urokinase plasminogen activator activity was detectable in solid
DS-sarcoma and in DS-sarcoma cells in vitro. There was no signif-
icant difference in band intensity when lysates from solid tumour
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Figure 1 Surface expression of uPA and uPAR on DS-sarcoma cells
determined by ﬂow cytometry. There are signiﬁcant differences in mean
ﬂuorescences between uPA or uPAR labelled cells and cells labelled with
idiotypic negative controls (n=35 per group, means+1 s.d.).
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sarcoma cells cultured in vitro. This may indicate that in solid
DS-sarcomas the tumour cells and not the stromal cells contribute
mainly to the proteolytic activity of uPA.
The uPA activity in solid DS-sarcomas was compared to the
activity in various normal tissues (lung, skeletal muscle, kidney,
liver) by zymography. All normal tissues exhibited some degree
of uPA activity. The amount of uPA expression varied signiﬁcantly
between the different tissues with low activity being found in skele-
tal muscle and liver in contrast to higher activities in kidney and
lung. In tumour tissue the uPA activity was much higher than in
any type of normal tissue examined. Standardised on 7 mg total
protein per sample, the uPA activity in DS-sarcoma was 4–20 fold
higher than in the normal tissues examined (Figure 3).
The impact of the oxygenation status on uPAR protein
expression and overall uPA activity
To examine the impact of the tumour oxygenation status on uPA
activity in vivo, a set-up for long-term inspiratory hypoxia was
used. Immediately after tumour implantation, rats were housed
in a hypoxic atmosphere containing 8% O2 /92% N2. Tumours
were compared to those in control animals breathing normal air
or 100% O2 during the whole period of tumour growth.
In a preceding study the oxygenation of DS-sarcomas under
these conditions was determined by computerised pO2 histography.
Mean median pO2 of DS-sarcomas grown in air was about 5 mm
Hg and signiﬁcantly decreased to 2 mm Hg upon inspiration of
92% N2/8% O2 (Kelleher et al, 1997), whereas breathing of pure
oxygen led to a signiﬁcant increase in the mean median pO2 up
to approximately 80 mm Hg (Thews et al, 1997). Various adaptive
processes can be expected to take place during long-term exposure
of the animals to a hypoxic atmosphere (8% O2). Under these
conditions, animals showed a polyglobulia with a RBC count of
8.4610
6/ml. The increased haematocrit however, results in a higher
viscous resistance to ﬂow which might worsen microcirculation
under these conditions. Due to adaption, the mean pO2 in
tumours of chronically hypoxic rats was slightly higher (3 mmHg)
compared to acute hypoxia, however still signiﬁcantly lower
compared to air breathing animals. There were no indications for
signiﬁcant improvements of tumour oxygenation by adaptive
mechanisms under low oxygen breathing conditions for days.
Using zymography, the uPA activity in solid DS-sarcomas was
compared between solid tumours which were grown under inspira-
tory hypoxia, normal room air or hyperoxia and in DS-sarcoma
cells in vitro which were incubated either under hypoxic or
normoxic conditions. Under in vitro and in vivo conditions the
uPA activity was comparable (Figure 4).
The surface expression of uPAR was measured in single cell
suspensions derived from solid DS-sarcomas. Mean ﬂuorescence
of DS-sarcoma cells was about 5–10 times higher than the back-
ground activity of the negative controls and even higher than the
signals derived from uPA expression (Figure 1). To evaluate the
impact of tumour oxygenation, uPAR expression of tumour cells
from solid tumours grown under 8% O2/92% N2 was compared
to uPAR expression in tumours grown in normal room air. There
was no enhanced surface expression in the hypoxic group
compared to tumours grown in normal air (n=50 per group, data
not shown). Therefore, a second series of hypoxic tumours (n=14;
grown under 8% O2/92% N2 – data not shown) was compared to
tumours (n=14) grown in rats which were housed in 100% O2 to
achieve greater differences in the oxygenation. In this latter series,
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Figure 4 Impact of the oxygenation status on uPA activity in DS-sarco-
ma cells in vitro and in solid tumours: In the supernatant, in whole cell lysates
of DS-sarcoma cells and in solid tumours the uPA activity was not signiﬁ-
cantly different under various conditions of O2 availability (culture medium:
eight independent samples/group, DS-sarcoma cell lysates: ﬁve indepen-
dent samples/group; solid tumours: inspiratory hypoxia (8% O2/92% N2)
vs room air in vivo: n=50/group, inspiratory hypoxia (8%O2/92% N2) vs hy-
peroxia (100% O2): n=14/group; values are means+1s.d.).
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detected by ﬂow cytometry.
Impact of tumour volume on uPA activity
No differences in uPA activity were detected between tumours
grown under different O2 conditions when the tumour size was
equally distributed between the groups. To evaluate the impact
of tumour volume, whole cell protein extracts of early stage small
tumours (0.5–1 ml tumour volume) were compared to more
advanced tumours (volumes of 2.0–3.5 ml). Each group encom-
passed samples from 16 different tumours. We found a
signiﬁcant, positive correlation between uPA activity and tumour
volume. The band intensity standardised on total protein concen-
tration per sample was substantially higher in the larger tumours
than in the smaller tumours (P=0.0001, Figure 5). The differences
in tumour oxygenation between small and large tumours in this
series has not been evaluated, but earlier measurements indicated
that the mean pO2 is decreased in larger experimental tumours
compared to smaller ones.
Impact of hypoxia on PAI-1 mRNA and protein levels
Plasminogen activator inhibitor type 1, the proteolytic antagonist
of uPA, was analysed on the protein and mRNA level. To evaluate
the impact of hypoxia on PAI-1 protein expression in vitro, PAI-1
protein was measured in supernatant of DS-sarcoma cells in vitro
grown under hypoxia for 24 h compared to control cultures
(normoxic conditions).
In supernatants of DS-sarcoma cells after hypoxic challenge a
two-fold increase of PAI-1 protein concentration was detected by
ELISA in ﬁve independent experiments (Figure 6), 200000 cells /
ml were used. After 24 h, the number of DS-sarcoma cells almost
doubled in normoxic controls, while hypoxia delayed cellular
growth, so that the number of cells in hypoxic cultures increased
only by 10–50% in that time period. The effect of hypoxia may
therefore, be even more pronounced when the secretion rate of
single cells is considered.
In the same experiments semi-quantitative multiplex RT–PCR
was used to determine whether this effect could additionally be
observed on the mRNA level. The amount of PAI-1 mRNA was
estimated as a ratio of PAI-1/b-actin mRNA in DS-sarcoma cells
in vitro immediately after exposure to hypoxia for 24 h. After
hypoxic challenge, PAI-1 bands were detected about 2–3 cycles
earlier in relation to the internal b-actin standard than in normoxic
controls. This effect was reproducible in three independent experi-
ments (Figure 7).
The impact of the tumour oxygenation status on PAI-1 protein
and mRNA concentrations was also analysed in vivo using inspira-
tory hypoxia (8% O2/92% N2), room air or hyperoxia (100% O2)
as described above. In each in vivo-experiment PAI-1 protein was
measured in whole cell protein extracts of solid DS-tumours, and
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chosen after tumour inoculation. The individual serum levels of
PAI-1 as well as the amount of PAI-1 protein in DS-tumours were
quite variable, but there were no signiﬁcant differences between the
median or mean values of both groups. RT–PCR also failed to
detect a signiﬁcant difference in mRNA expression between
tumours grown under hypoxic or hyperoxic conditions (data not
shown).
DISCUSSION
We detected uPA, uPAR and PAI-1 in solid DS-sarcomas in vivo
and in primary cultures of DS-sarcoma cells in vitro. In contrast
to some other tumour entities (Andreasen et al, 1997), in DS-
sarcomas the tumour cells themselves generate all three compo-
nents of the uPA system. Urokinase plasminogen activator-
receptor is expressed on the cell surface of DS-sarcoma cells in vitro
or on single cell suspensions derived from solid tumours, PAI-1
protein and mRNA are detectable in solid tumours and DS-sarco-
ma cells in vitro. Urokinase plasminogen activator activity in whole
cell extracts from DS-sarcoma cells in vitro and from solid DS-
tumours in vivo is similar, indicating that the tumour cells are
the main source of uPA activity. Therefore, a co-operation between
tumour and stromal cells, with different cell types providing differ-
ent components of the uPA system (as described, for instance, in
colon cancer (Sordat el al, 1997)), is not necessarily a prerequisite
for the functionality of the uPA system in DS-sarcoma. The uPA
activity in DS-sarcomas is signiﬁcantly higher than in all other
normal tissues examined, which may be an indication for its func-
tional role in tumour progression.
The question arises as to which mechanism can up-regulate
uPA-induced proteolysis under pathological conditions in malig-
nant tumours. The higher expression may be a result ultimately
deducible from oncogenic transformation. A wide variety of
hormones, growth factors and cytokines are up-regulated as a
consequence of oncogenic transformation and are known to regu-
late the expression of components of the uPA system (Andreasen et
al, 1997). But a further pathway not directly related to oncogenic
alterations can not yet ruled out. The special conditions of the
tumour micromilieu, especially tumour hypoxia, are known to
have an impact on the expression of a variety of genes and the
activity of many gene products (Dachs and Tozer, 2000; Koong
et al, 2000; Semenza, 2000; Ho ¨ckel and Vaupel, 2001).
In the present study, incubation of DS-sarcoma cells for 24 h
under hypoxia in vitro induced a signiﬁcant up-regulation of
PAI-1 protein and mRNA. These results are consistent with the
observation that PAI-1 is enhanced in cells lacking a functional
von-Hippel-Lindau (VHL) gene (Los et al, 1999). pVHL triggers
the proteolytic degradation of the hypoxia-inducible factor subunit
1a (HIF-1a) via an ubiquitin-proteasome pathway thereby regulat-
ing the transcriptional activity of the most important hypoxia-
inducible transcription factor. In pVHL deﬁcient cells, HIF-1 is
constitutively upregulated; therefore these cells might behave in
some aspects like cells under hypoxic stress.
At a glance, the relation between hypoxia and PAI-1 upregula-
tion seems paradoxical, because the role of PAI-1 as an inhibitor
of uPA proteolytic function may also suggest that PAI-1 is predo-
minantly an inhibiting factor of malignant progression in general.
However, clinical data contradict this assumption. Far more studies
report a positive correlation between high expression of PAI-1 and
negative outcome than vice versa (Reuning et al, 1998).
Although PAI-1 inhibits proteolytic activity of uPA, this mole-
cule seems to be a marker of aggressiveness in malignant
tumours. PAI-1 mRNA is not detectable in low-grade astrocytoma
or normal brain tissue by Northern blot, but it is increased in
high-grade astrocytomas, and is most pronounced in glioblastoma
multiforme (Yamamoto et al, 1994). Further biological functions of
PAI-1 beyond involvement in proteolysis and extracellular matrix
(ECM) degradation may explain this paradoxical ﬁnding. There
are indications that PAI-1 may be crucial for neoangiogenesis in
tumours. Impaired tumour growth and reduced angiogenesis have
been described in PAI-1 deﬁcient host mice (Bajou et al, 1998).
Plasminogen activator inhibitor type 1 is also related to cell
adhesion and motility (Stahl, 1997), and can interfere with the
binding between cells and proteins of the extracellular matrix. It
reduces the binding between uPAR and vitronectin (VN), and also
the binding between integrins of the av family by masking a soma-
tomedin B-like domain (Chapman, 1997). In neuroblastoma, PAI-1
is positively correlated with metastatic behaviour. Sugiura et al
(1999) explained this effect by the action of PAI-1 as an anti-
detachment factor which interrupts the binding to vitronectin
and enhances migration toward ﬁbronectin-rich matrices.
Recent experiments described an anti-apoptotic effect of PAI-1
on tumour and benign cell lines (Kwaan et al, 2000). In the present
study, DS-sarcoma were seen to be able to survive hypoxic stress,
when they had already passed through several cycles of hypoxia
and reoxygenation. The relevance of PAI-1 in this phenomenon
still has to be determined, but it may be possible that the upregula-
tion of PAI-1 in hypoxia promotes malignant progression and
metastasis formation also by additionally increasing resistance to
apoptosis (Ho ¨ckel et al, 1999).
In vitro assays for invasion showed that not the absolute amount
of a single component, but rather the optimal relation between
uPA, uPAR and PAI-1 is important for the ability of tumour cells
to invade ECM matrixes (for a review see Andreasen et al, 1997).
Although hypoxia enhances PAI-1 expression in vitro, the uPA
activity in whole cell lysates or culture supernatants was not dimin-
ished.
These in vitro effects could not be detected in vivo under the condi-
tions described above. The reason for the discrepancy between the in
vitro and in vivo results is not yet clear. Tumour oxygenation in vivo is
spatially quite heterogeneous, even within a single tumour, and also
varies over time. In addition to diffusion-limited (chronic) hypoxia
in tumours, changes in vascular patency can generate areas of ischae-
mic (acute) hypoxia (for a review see Vaupel et al, 1989). Therefore,
RT–PCR or ELISA are probably not able to detect such differences in
vivo, because they provide only a ‘global picture’ of protein or mRNA
expression at a distinct point in time.
Another reason could be that even globally well-oxygenated
tumours exhibit microareas of hypoxia, which can lead to an
induction of gene expression. In air breathing animals, solid DS-
sarcomas exhibit mean pO2 values of about 5 mm Hg, which is
apparently low compared to normal tissue, but which is compar-
able to the oxygenation values of a variety of human tumours
measured in clinical situations. Upon breathing 100% O2, the
mean pO2 of DS-sarcomas could be signiﬁcantly improved, but
poorly oxygenated microareas may still exist under such experi-
mental conditions. Kietzmann et al (1999) found, that the
incubation of cells in an 8% O2 atmosphere is able to induce
PAI-1 mRNA in rat hepatocytes in vitro, which indicates that prob-
ably even rather moderate degrees of tumour hypoxia may able to
enhance PAI-1 expression. In any case this result also indicates that
global parameters (such as PAI-1 or VEGF serum levels) may not
be a very reliable marker of tumour hypoxia.
In vivo, uPA activity in DS-sarcomas was found to strongly
correlate with tumour volume. Small tumours exhibited a signiﬁ-
cantly lower uPA activity per mg extracted whole cell protein
than larger tumours. This may be an indication that uPA activity
is not only involved in early events such as basement membrane
degradation during transition from in situ carcinomas to invasive
tumours, but also in later events of malignant progression such
as invasion of tissue barriers or intravasation/extravasation of
tumour cells.
The increase of uPA activity with tumour size could be a result
of an autocrine and/or paracrine positive feedback loop within a
solid tumour. TGFb is a possible candidate for a cytokine involved
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plasmin-derived proteolysis, and active TGFb induces an up-regu-
lation of uPA transcription. However, a hostile tumour
micromilieu in larger tumours could also be responsible for this
effect. The proportion of hypoxic areas, or areas with poor blood
supply, glucose depletion and extracellular acidosis, increases with
tumour size in experimental tumours and may also lead to an
up-regulation of uPA activity.
In conclusion, these results suggest that the components of the
uPA system are up-regulated in rat DS-sarcoma. Micromilieu
factors such as hypoxia may contribute to the upregulation of some
components of the system, although in this study the in vitro
results could not be reproduced in the in vivo system. The expres-
sion pattern of components of the uPA system in different tumour
entities is quite variable and the results from one entity could not
necessarily be extrapolated to another. But since up-regulation of
the uPA system is a relatively common feature in many solid
tumours, interferences with this system may be a possible thera-
peutic approach in at least some entities. It may be possible to
combine inhibitors of the uPA system with radiotherapy, as these
modalities represent different therapeutic principles and therefore
only limited overlapping toxicity should be expected.
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